MA50972A - Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide - Google Patents

Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide

Info

Publication number
MA50972A
MA50972A MA050972A MA50972A MA50972A MA 50972 A MA50972 A MA 50972A MA 050972 A MA050972 A MA 050972A MA 50972 A MA50972 A MA 50972A MA 50972 A MA50972 A MA 50972A
Authority
MA
Morocco
Prior art keywords
pyrazol
ylmethyl
pyridin
acetamide
cyclopropyl
Prior art date
Application number
MA050972A
Other languages
English (en)
Inventor
Bibia Heidmann
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA50972A publication Critical patent/MA50972A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050972A 2017-07-05 2018-07-04 Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide MA50972A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017066806 2017-07-05

Publications (1)

Publication Number Publication Date
MA50972A true MA50972A (fr) 2020-10-14

Family

ID=63079885

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050972A MA50972A (fr) 2017-07-05 2018-07-04 Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide

Country Status (17)

Country Link
US (2) US11059803B2 (fr)
EP (1) EP3649117B1 (fr)
JP (2) JP2020525475A (fr)
KR (1) KR102645911B1 (fr)
CN (1) CN110831932A (fr)
AU (1) AU2018296423B2 (fr)
BR (1) BR112020000099A2 (fr)
CA (1) CA3067489A1 (fr)
CL (1) CL2020000002A1 (fr)
EA (1) EA202090193A1 (fr)
IL (1) IL271764B2 (fr)
MA (1) MA50972A (fr)
MY (1) MY206357A (fr)
PH (1) PH12020500040A1 (fr)
SG (1) SG11201912881SA (fr)
UA (1) UA126582C2 (fr)
WO (1) WO2019008034A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
CA3050348A1 (fr) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd Nouveau procede de synthese de 1-aryl-1-trifluoromethylcyclopropanes
EA202090193A1 (ru) * 2017-07-05 2020-06-03 Идорсия Фармасьютиклз Лтд Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида
TW202128158A (zh) 2019-12-20 2021-08-01 瑞士商愛杜西亞製藥有限公司 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物
WO2023022504A1 (fr) * 2021-08-17 2023-02-23 한국과학기술원 Oligonucléotide antisens ciblant le gène cav3.1 et ses utilisations
WO2023240205A1 (fr) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Composés deutérés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
CN107074822B (zh) 2014-09-15 2020-01-03 爱杜西亚药品有限公司 作为t型钙通道阻断剂的三唑化合物
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
CA3050348A1 (fr) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd Nouveau procede de synthese de 1-aryl-1-trifluoromethylcyclopropanes
EA202090193A1 (ru) * 2017-07-05 2020-06-03 Идорсия Фармасьютиклз Лтд Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида

Also Published As

Publication number Publication date
BR112020000099A2 (pt) 2020-07-07
WO2019008034A1 (fr) 2019-01-10
AU2018296423A1 (en) 2020-02-20
EA202090193A1 (ru) 2020-06-03
SG11201912881SA (en) 2020-01-30
IL271764B1 (en) 2023-06-01
IL271764B2 (en) 2023-10-01
US11059803B2 (en) 2021-07-13
US20200165221A1 (en) 2020-05-28
JP2023123679A (ja) 2023-09-05
CN110831932A (zh) 2020-02-21
KR102645911B1 (ko) 2024-03-08
UA126582C2 (uk) 2022-11-02
AU2018296423B2 (en) 2022-07-28
CA3067489A1 (fr) 2019-01-10
IL271764A (en) 2020-02-27
PH12020500040A1 (en) 2020-10-12
US11555025B2 (en) 2023-01-17
EP3649117A1 (fr) 2020-05-13
JP2020525475A (ja) 2020-08-27
CL2020000002A1 (es) 2020-07-31
KR20200018698A (ko) 2020-02-19
MY206357A (en) 2024-12-12
EP3649117B1 (fr) 2024-10-09
US20210300894A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
IL280782A (en) Inhibiting αv β6 integrin
IL274488B1 (en) Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL271764A (en) Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
IL271726A (en) Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2, 6-doxopyridin-3-yl)-1-oxoisoinodolin-5-yl)methyl)2-2-difluoroacetamide
EP3431075A4 (fr) Forme galénique d'édaravone
GB201609607D0 (en) Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
PL3464276T3 (pl) Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
IL252900B (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
LT3448849T (lt) Indazolo sintezė
EP3263553A4 (fr) Modification cristalline de n-(2- (3-phényluréido)phényl)-benzènesulfonamide et matériau d'enregistrement l'utilisant
ZA201804482B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
DK3395342T3 (da) Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
EP3685821A4 (fr) Composition de colorant capillaire liquide
PL3630725T3 (pl) Postać krystaliczna n-butylodeoksygalaktonojirymycyny
EP3313396A4 (fr) Inhibiteurs de la kinase du récepteur couplé aux protéines g et méthodes d'utilisation de ceux-ci
PT3752129T (pt) Composição multiuso de torasemida
EP3853665A4 (fr) Estimation d'aberrations asymétriques
HK40025427A (en) Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
EP3773536A4 (fr) Dérivés 1,4-substitués de l'isoquinoline utilisés comme inhibiteurs de l'interaction protéine-protéine entre keap1/nrf2
PL3643704T3 (pl) Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu